Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re gearing up for one final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! Source: Shutterstock But hold up just a minute. Let’s r...
AL002 is a Patented Method Using a Mutant-Peptide Sensitized Cell as a Cell-Based Therapeutic Vaccine Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatmen...
Recently IPO’d biotech firm Alzamend Neuro ([[ALZN]] -13.3%) has bounced back from early losses to hover above its IPO price of $5.00 per share.However, the stock dropped to a session low of $4.85 apiece in morning hours, indicating a ~3.0% decline from the IPO price.The comp...
Alzamend Neuro Inc. (NASDAQ:ALZN) traded today at a new 52-week low of $4.85. This new low was reached on above average trading volume as 2.6 million shares traded hands, while the average 30-day volume is approximately 1.9 million shares. Alzamend Neuro Inc. share prices have moved betw...
Gainers: Freeline Therapeutics (FRLN) +88%, Cytokinetics CYTK +49%, NRx Pharmaceuticals NRXP +37%, Allied Healthcare Products (AHPI) +19%, Aethlon Medical (AEMD) +16%.Losers: China SXT Pharmaceuticals (SXTC) -21%, Atossa Therapeutics (ATOS)...
Gainers: China SXT Pharmaceuticals (SXTC) +37%, Trinity Biotech (TRIB) +11%, Moderna (MRNA) +9%, Aptevo Therapeutics (APVO) +9%, Apollo Medical (AMEH) +4%.Losers: FibroGen (FGEN) -45%, Neptune Wellness Solutions (NEPT) -20%, Atossa Therapeutic...
FibroGen (FGEN) -33% after setback for kidney disease therapy in FDA AdCom meetingLiquid Media (YVR) -17% on Q2 earnings releaseATA Creativity (AACG) -12%.Corvus Pharmaceuticals (CRVS) -10% after scrapping late-stage mupadolimab COVID-19 trialNeptune Wellness Sol...
Alzamend Celebrates Successful Initial Public Offering and Corporate Milestone Alzamend Neuro ®, Inc. (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), a preclinical stage biopharmaceutical company, today announced that its Chairm...
Gainers: Aerpio Pharmaceuticals (ARPO) +54%, GBS (GBS) +25%, 9 Meters Biopharma (NMTR) +19%, Alterity Therapeutics (ATHE) +10%, F-star Therapeutics (FSTX) +9%.Losers: Virpax Pharmaceuticals (VRPX) -13%, Nephros (NEPH) -12%, ...
360 DigiTech (QFIN) -21%.Vista Gold (VGZ) -18% after secures $13.5M capital raise.Newegg Commerce (NEGG) -17%.BSQUARE (BSQR) -16%.Virpax Pharmaceuticals (VRPX) -15%.Marin Software (MRIN) -15%.LexinFintech (LX) -14%.Blonder Tongue Laboratories (BDR) -14%.Exela Technologies (XELA...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...